According to this research, the Asia Pacific biopsy device market shows an upward trend and is likely to exhibit a CAGR of 7.99% during the forecast period of 2019-2027.
India, China, Japan, South Korea, ASEAN countries, Australia & New Zealand and countries in rest of Asia-Pacific together form the market for biopsy devices in the APAC region.
In recent years, an increase in the number of cancer cases in APAC has intensified research in the disease to detect the condition early and to treat it by developing advanced solutions using biopsy tests. Furthermore, there exists a probability of leading vendors in the market shifting their base to the Asia-Pacific region to gain advantage of the lucrative proposition of cheaper land & material cost, easily available workforce and access to a vast patient base. This will make their solutions available to end-users at much lower costs. Therefore, economic developments and growing government support, with a possibility of biopsy vendors migrating their operational bases to the region, have opened new growth avenues for biopsy solution providers in the emerging markets.
In countries such as China, India, and Thailand, oral cavity cancer is quite prevalent due to the use of smokeless tobacco products. Also, the stomach cancer rates are higher in these regions due to the high prevalence of Helicobacter pylori infection and probably due to dietary patterns. Over the forecasting period, the Asia-Pacific region with its broader customer base will dominate the global market in terms of demand for the biopsy procedure segment.
Few of the prime players in this market are QIAGEN N.V., B. Braun Melsungen AG, Becton, Dickinson, Ad-Tech Medical Instrument Corp., Cardinal Health, Inc., I.M.S. Internazionale Medico Scientifica SRL, Boston Scientific Corporation, Planmeca Oy, C. R. Bard, Inc. and Argon Medical Devices, Inc.
Key Topics Covered
1. Asia-Pacific Biopsy Device Market - Summary
2. Industry Outlook
2.1. Market Definition
2.2. Porter's Five Forces Outlook
2.3. Vendor Scorecard
2.4. Market Attractiveness Matrix
2.5. Key Insights
2.6. Patents Outlook
2.7. Market Drivers
2.7.1. Prevalence of Chronic Diseases on the Rise
2.7.2. Growing Public Knowledge About Disease Transmission
2.7.3. Increasing Diagnostic Centers
2.8.1. Dearth of Skilled Professionals
2.8.2. Reimbursement Issues
2.9.1. Increasing Incidence of Liver Diseases
2.10. Market Challenges
2.10.1. Limited Technical Skills
2.10.2. High Cost of Biopsy Techniques
3. Biopsy Device Market Outlook - By Device Type
3.1. Breast Biopsy
3.1.1. Vacuum-Assisted Core Biopsy (VAB)
3.1.2. Core Needle Biopsy (CNB)
3.1.3. Fine Needle Biopsy
3.2. Gastrointestinal (GI) Biopsy
3.3. Soft Tissue Biopsy Needles
3.4. Bronchial Biopsy
3.5. Gynecological Biopsy Device
3.6. Robotic Guidance System
3.7. Other Devices
4. Biopsy Device Market Outlook - By Therapeutic Area
4.1. Breast Biopsy
4.2. GI Biopsy
4.3. Prostate Biopsy
4.4. Liver Biopsy
4.5. Lung Biopsy
4.6. Kidney Biopsy
4.7. Gynecological Biopsy
4.8. Other Therapeutic Area
5. Biopsy Device Market Outlook - By Display Technologies
5.1. MRI-Guided Biopsy
5.2. Stereotactic-Guided Biopsy
5.3. Ultrasound-Guided Biopsy
5.4. CT-Guided Biopsy
5.5. Other Display Technologies
6. Biopsy Device Market Outlook - By End-User
6.1. Diagnosis Center
7. Biopsy Device Market - Regional Outlook
7.4. South Korea
7.5. Australia & New Zealand
7.6. Asian Countries
7.7. Rest of APAC
8. Company Profiles
8.1. Ad-Tech Medical Instrument Corp.
8.2. Argon Medical Devices Inc.
8.3. B. Braun Melsungen AG
8.4. Becton, Dickinson
8.5. Boston Scientific Corporation
8.6. Cardinal Health Inc.
8.7. C. R. Bard Inc.
8.8. I.M.S. Internazionale Medico Scientifica S.r.l.
8.9. Planmeca Oy
8.10. Qiagen N.V.
9. Methodology & Scope
9.1. Research Scope
9.2. Sources of Data
9.3. Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/nmczmu